Literature DB >> 8861832

A second trefoil protein, ITF/hP1.B, is transcribed in human breast cancer.

B Theisinger1, G Seitz, S Dooley, C Welter.   

Abstract

Trefoil proteins form a specific group of stable secreted polypeptides. They are expressed in a lot of human cancers and during inflammatory processes of the gastrointestinal tract. Recently a new human trefoil protein, ITF/hP1.B, was isolated. Until now no studies of the activity of this gene in human solid tumors exist. In our examination we show for the first time that this gene is transcribed in human breast cancer. In contrast to another trefoil protein, pS2, the expression of ITF/hP1.B is not under control of estrogen in the human breast cancer cell line MCF-7. We suggest that the gene activity of ITF/hP1.B in addition to pS2 expression may be an improved prognostic marker in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861832     DOI: 10.1007/bf01806668

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

1.  Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.

Authors:  J Hurlimann; S Gebhard; F Gomez
Journal:  Histopathology       Date:  1993-09       Impact factor: 5.087

2.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

Authors:  P Masiakowski; R Breathnach; J Bloch; F Gannon; A Krust; P Chambon
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

3.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

4.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.

Authors:  M C Rio; J P Bellocq; J Y Daniel; C Tomasetto; R Lathe; M P Chenard; A Batzenschlager; P Chambon
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

5.  pS2 protein and steroid hormone receptors in invasive breast carcinomas.

Authors:  F C Koerner; D E Goldberg; S M Edgerton; L H Schwartz
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

6.  Expression pattern of breast-cancer-associated protein pS2/BCEI in colorectal tumors.

Authors:  C Welter; B Theisinger; M C Rio; G Seitz; G Schüder; N Blin
Journal:  Int J Cancer       Date:  1994-01-02       Impact factor: 7.396

7.  Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract.

Authors:  M C Rio; M P Chenard; C Wolf; L Marcellin; C Tomasetto; R Lathe; J P Bellocq; P Chambon
Journal:  Gastroenterology       Date:  1991-02       Impact factor: 22.682

8.  Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.

Authors:  V Cappelletti; D Coradini; E Scanziani; E Benini; R Silvestrini; G Di Fronzo
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

9.  Detection of pS2 messenger RNA in gynecological cancers.

Authors:  S J Wysocki; E Hahnel; A Masters; V Smith; A J McCartney; R Hahnel
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

10.  Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma.

Authors:  B Theisinger; C Welter; G Seitz; M C Rio; R Lathe; P Chambon; N Blin
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  2 in total

1.  Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.

Authors:  Katherine S Wilson; Helen Roberts; Russell Leek; Adrian L Harris; Joseph Geradts
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

2.  Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas.

Authors:  E Bignotti; A Ravaggi; R A Tassi; S Calza; E Rossi; M Falchetti; C Romani; E Bandiera; F E Odicino; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.